Lexicon Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LXRX Nasdaq 2836 www.lexpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lexicon Pharmaceuticals, Inc.

How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates - Jun 4th, 2026 7:14 am
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions - Jun 3rd, 2026 6:00 am
Lexicon (LXRX) Q1 2026 Earnings Transcript - Jun 1st, 2026 2:40 pm
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - May 28th, 2026 6:30 am
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX) - May 22nd, 2026 12:43 pm
Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed - May 13th, 2026 12:13 am
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - May 12th, 2026 6:30 am
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones - May 9th, 2026 10:00 pm
Lexicon Pharmaceuticals Q1 Earnings Call Highlights - May 8th, 2026 1:25 am
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1 - May 7th, 2026 6:50 am
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates - May 7th, 2026 5:30 am
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital - May 4th, 2026 2:05 pm
Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 Trial - May 3rd, 2026 5:08 pm
Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851 - May 1st, 2026 3:23 am
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - Apr 30th, 2026 6:00 am
How The Lexicon Pharmaceuticals (LXRX) Investment Story Is Shifting With Pilavapadin And LX9851 - Apr 27th, 2026 12:04 am
Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data - Apr 23rd, 2026 1:30 am
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting - Apr 17th, 2026 6:00 am
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions - Apr 6th, 2026 6:17 pm
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug - Mar 24th, 2026 8:31 am